Anne Amberg
Adult Health · Putnam, CTNPI 1538257779
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,435 and has fallen 59.1% since, to $995 in 2025. Among adult health clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 129 payments — averaging $44.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Corcept Therapeutics$569
- AstraZeneca$550
- Novo Nordisk$484
- Amgen$293
- Boehringer Ingelheim$289
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,650100%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $1,073 |
| Corcept Therapeutics | 7 | $569 |
| AstraZeneca | 7 | $550 |
| Novo Nordisk | 13 | $484 |
| Amgen | 5 | $293 |
| Boehringer Ingelheim | 10 | $289 |
| Otsuka America Pharmaceutical, Inc. | 6 | $288 |
| Lilly USA, LLC | 8 | $272 |
| GSK | 4 | $234 |
| Actelion Pharmaceuticals US, Inc. | 2 | $231 |
| Teva Pharmaceuticals USA, Inc. | 2 | $175 |
| Johnson & Johnson | 1 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $125 |
| Bayer | 1 | $124 |
| Sanofi | 1 | $120 |
| Ardelyx, Inc. | 1 | $90 |
| Gilead | 2 | $79 |
| Astellas Pharma US Inc | 4 | $77 |
| Endo Pharmaceuticals Inc. | 3 | $71 |
| Phathom Pharmaceuticals, Inc. | 1 | $69 |
| Biohaven Pharmaceuticals, Inc. | 3 | $68 |
| Amarin Pharma, Inc. | 4 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Eisai Inc. | 2 | $35 |
| Merck | 2 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,678 in reported general payments places this provider in the 90th percentile of 418 adult health providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $14,735 |
| Clobetasol Propionate | 12 | $529 |
| Amlodipine Besylate | 13 | $192 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $152 |
| Rosuvastatin Calcium | 11 | $139 |
| Doxycycline Hyclate | 11 | $132 |
| Duloxetine Hcl | 11 | $123 |
| Atorvastatin Calcium | 11 | $65 |
| Amoxicillin | 14 | $61 |
| Hydrochlorothiazide | 13 | $57 |
| Prednisone | 14 | $19 |
| Lisinopril | 11 | $13 |
| Meloxicam | 16 | $10 |
Paid to pharmacies, not to this prescriber.
Other adult health in Putnam
- Vanmaly SangasyPutnam$6K
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Andrea LauterNew London$32K
- Megan CarlucciManchester$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.